CL2017001233A1 - Oligonucleótidos antisentido como inhibidores de la señalización del tgf-r - Google Patents

Oligonucleótidos antisentido como inhibidores de la señalización del tgf-r

Info

Publication number
CL2017001233A1
CL2017001233A1 CL2017001233A CL2017001233A CL2017001233A1 CL 2017001233 A1 CL2017001233 A1 CL 2017001233A1 CL 2017001233 A CL2017001233 A CL 2017001233A CL 2017001233 A CL2017001233 A CL 2017001233A CL 2017001233 A1 CL2017001233 A1 CL 2017001233A1
Authority
CL
Chile
Prior art keywords
tgf
signaling
inhibitors
antisense oligonucleotides
nucleotides
Prior art date
Application number
CL2017001233A
Other languages
English (en)
Inventor
Markus Hossbach
Monika Krampert
Hans Lothar Arth
Original Assignee
Neurovision Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurovision Pharma GmbH filed Critical Neurovision Pharma GmbH
Publication of CL2017001233A1 publication Critical patent/CL2017001233A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A OLIGONUCLEÓTIDOS ANTISENTIDO QUE TIENEN UNA LONGITUD DE AL MENOS 10 NUCLEÓTIDOS, EN DONDE AL MENOS DOS DE LOS NUCLEÓTIDOS SON LNAs, SU USO CORNO INHIBIDORES DE LA SEÑALIZACIÓN DE TGF-R, COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN TALES OLIGONUCLEÓTIDOS ANTISENTIDO Y EL USO PARA PROFILAXIS Y TRATAMIENTO DE ENFERMEDADES NEUROLÓGICAS, NEURODEGENERATIVAS, FIBRÓTICAS E HIPERPROLIFERATIVAS.</p>
CL2017001233A 2014-11-16 2017-05-15 Oligonucleótidos antisentido como inhibidores de la señalización del tgf-r CL2017001233A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14193368.9A EP3020813A1 (en) 2014-11-16 2014-11-16 Antisense-oligonucleotides as inhibitors of TGF-R signaling

Publications (1)

Publication Number Publication Date
CL2017001233A1 true CL2017001233A1 (es) 2017-12-15

Family

ID=51900289

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017001233A CL2017001233A1 (es) 2014-11-16 2017-05-15 Oligonucleótidos antisentido como inhibidores de la señalización del tgf-r
CL2019000980A CL2019000980A1 (es) 2014-11-16 2019-04-11 Oligonucleotidos antisentido de al menos 10 nucleotidos que inhiben de la señalización del gen tgf-ii o una región del arnm que lo codifica. (divisional solicitud 201701233).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2019000980A CL2019000980A1 (es) 2014-11-16 2019-04-11 Oligonucleotidos antisentido de al menos 10 nucleotidos que inhiben de la señalización del gen tgf-ii o una región del arnm que lo codifica. (divisional solicitud 201701233).

Country Status (22)

Country Link
US (4) US10363266B2 (es)
EP (3) EP3020813A1 (es)
JP (2) JP6832285B2 (es)
KR (2) KR102417601B1 (es)
CN (2) CN113151261A (es)
AU (3) AU2015345006B2 (es)
BR (1) BR112017006201B1 (es)
CA (2) CA3201845C (es)
CL (2) CL2017001233A1 (es)
CY (1) CY1121110T1 (es)
DK (1) DK3218488T3 (es)
ES (1) ES2705066T3 (es)
HU (1) HUE041793T2 (es)
IL (2) IL251565B (es)
MX (2) MX2017006369A (es)
MY (1) MY181404A (es)
PL (1) PL3218488T3 (es)
PT (1) PT3218488T (es)
RU (1) RU2717454C2 (es)
SG (1) SG11201703127SA (es)
TR (1) TR201900844T4 (es)
WO (1) WO2016075339A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3020813A1 (en) * 2014-11-16 2016-05-18 Neurovision Pharma GmbH Antisense-oligonucleotides as inhibitors of TGF-R signaling
WO2019010226A1 (en) * 2017-07-03 2019-01-10 The Regents Of The University Of California CHEMICALLY MODIFIED MICROARN-214 ANTISENS AND USE THEREOF FOR THE TREATMENT OF HEMORRHAGIC RECTOCOLITE AND PROCTITE
MX2020006430A (es) * 2017-12-22 2020-09-17 Roche Innovation Ct Copenhagen As Oligonucleotidos que comprenden un enlace internucleosidico de fosforoditioato.
WO2019122277A1 (en) * 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Novel thiophosphoramidites
TW201934750A (zh) * 2017-12-22 2019-09-01 丹麥商羅氏創新中心哥本哈根有限公司 包含二硫代磷酸酯核苷間連結之間隙子(gapmer)寡核苷酸
JP2023548597A (ja) * 2020-10-29 2023-11-17 エー． ガルシア－ブランコ，マリアーノ がんを処置するための可溶性インターロイキン－７受容体（ｓＩＬ７Ｒ）変調療法
CN114588160A (zh) * 2020-12-07 2022-06-07 四川大学华西医院 具有抗肺纤维化作用的次黄碱衍生物
CN113992687B (zh) * 2021-12-28 2022-04-08 浙江宇视科技有限公司 智能业务集群调度方法、装置、电子设备及存储介质

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0885016B1 (en) 1996-02-19 2003-04-16 Amersham Health AS Thermally stabilized contrast agent
US20030064944A1 (en) 2001-06-21 2003-04-03 Isis Pharmaceuticals Inc. Antisense modulation of transforming growth factor beta receptor II expression
EP2141233B1 (en) 2002-11-18 2016-10-19 Roche Innovation Center Copenhagen A/S Antisense design
WO2005019422A2 (en) * 2003-08-13 2005-03-03 The Board Of Trustees Of The University Of Illinois Silencing of tgf-beta receptor type ii expression by sirna
BRPI0507528A (pt) * 2004-02-09 2007-07-03 Regenion Gmbh oligonucleotìdeos, preparação farmacêutica, uso de pelo menos um oligonucleotìdeo e método para identificar um composto
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
KR20130042043A (ko) 2006-01-27 2013-04-25 아이시스 파마수티컬즈 인코포레이티드 6-변형된 바이시클릭 핵산 유사체
CA3042781C (en) 2006-04-03 2021-10-19 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
WO2007134181A2 (en) 2006-05-11 2007-11-22 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
CN101554074B (zh) 2006-10-30 2012-08-22 诺基亚公司 为用户设备提供运营商控制的移动性的方法、设备和系统
WO2008109546A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tgfbr gene expression and uses thereof
US8278425B2 (en) 2007-05-30 2012-10-02 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
ES2386492T3 (es) 2007-06-08 2012-08-21 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos carbocíclicos
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
US20110119781A1 (en) * 2008-07-15 2011-05-19 Birgit Bramlage Compositions and Methods for Inhibiting Expression of TGF-BETA Receptor Genes
CN102762215A (zh) * 2009-10-16 2012-10-31 葛兰素集团有限公司 Hbv反义抑制剂
WO2011154542A1 (en) * 2010-06-11 2011-12-15 Artisense Pharma Gmbh Method for selective oligonucleotide modification
US9115371B2 (en) * 2011-08-18 2015-08-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reduction of TGF beta signaling in myeloid cells in the treatment of cancer
CN104004762B (zh) * 2014-05-20 2016-03-30 南京医科大学附属南京儿童医院 Tgf-r反义序列及其在制备抗气道炎症反应药物中的应用
EP3020813A1 (en) * 2014-11-16 2016-05-18 Neurovision Pharma GmbH Antisense-oligonucleotides as inhibitors of TGF-R signaling

Also Published As

Publication number Publication date
MX2020011476A (es) 2020-12-07
CL2019000980A1 (es) 2019-07-12
KR102310899B1 (ko) 2021-10-12
JP6832285B2 (ja) 2021-02-24
IL269151B1 (en) 2023-04-01
SG11201703127SA (en) 2017-06-29
MX2017006369A (es) 2018-02-16
US20220143071A1 (en) 2022-05-12
IL251565A0 (en) 2017-05-29
KR20210113697A (ko) 2021-09-16
ES2705066T3 (es) 2019-03-21
US20170319614A1 (en) 2017-11-09
CN107002082B (zh) 2021-02-02
CA3201845C (en) 2024-02-20
BR112017006201A2 (pt) 2018-05-02
MY181404A (en) 2020-12-21
IL251565B (en) 2020-05-31
CY1121110T1 (el) 2019-12-11
US20160138029A1 (en) 2016-05-19
JP6983343B2 (ja) 2021-12-17
HUE041793T2 (hu) 2019-05-28
BR112017006201B1 (pt) 2023-04-18
DK3218488T3 (en) 2019-01-14
TR201900844T4 (tr) 2019-02-21
CN113151261A (zh) 2021-07-23
WO2016075339A1 (en) 2016-05-19
PL3218488T3 (pl) 2019-04-30
EP3418385A1 (en) 2018-12-26
JP2018501816A (ja) 2018-01-25
EP3218488B1 (en) 2018-10-24
EP3218488A1 (en) 2017-09-20
RU2717454C2 (ru) 2020-03-23
AU2015345006B2 (en) 2020-11-05
AU2020257116B2 (en) 2023-01-12
AU2015345006A1 (en) 2017-06-08
RU2017120481A3 (es) 2019-05-27
IL269151B2 (en) 2023-08-01
CA3201845A1 (en) 2016-05-19
AU2020257116A1 (en) 2020-11-19
AU2020260380A1 (en) 2020-11-19
AU2020260380B2 (en) 2023-04-13
CA2964834A1 (en) 2016-05-19
EP3020813A1 (en) 2016-05-18
JP2021072841A (ja) 2021-05-13
US20190314401A1 (en) 2019-10-17
CN107002082A (zh) 2017-08-01
IL269151A (en) 2019-11-28
RU2017120481A (ru) 2018-12-18
CA2964834C (en) 2023-08-08
KR102417601B1 (ko) 2022-07-05
US11213541B2 (en) 2022-01-04
US10363266B2 (en) 2019-07-30
PT3218488T (pt) 2019-01-21
KR20170095230A (ko) 2017-08-22

Similar Documents

Publication Publication Date Title
CL2017001233A1 (es) Oligonucleótidos antisentido como inhibidores de la señalización del tgf-r
ES2753201T8 (es) Secuencias UTR 3&#39; para la estabilización del ARN
IL262199B (en) Oligonucleotides to treat eye disease
CL2017003404A1 (es) Compuestos antibacterianos
CL2018000128A1 (es) Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
IL268422A (en) Targeted oligonucleotides
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
MA48448A (fr) Dérivés de quinazoline utilisés pour traiter le vih
CL2016000424A1 (es) Métodos y composiciones para el arn-guiado tratamiento de la infección por vih
IL257091B (en) Targeted oligonucleotides
DOP2015000201A (es) Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos
BR112017023853A2 (pt) composições de nanopartícula para terapia sustentada.
IL250016B (en) Antisense oligonucleotides for the treatment of type 2 syndrome
ES2769863T8 (es) 7-hidroxi-cannabidivarín (7-OH-CBDV) para usar en el tratamiento de la epilepsia
DOP2016000173A (es) Heteroarilos y usos de estos
CU24389B1 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
MA40551A (fr) Composés actifs envers des bromodomaines
CL2016002841A1 (es) Desnitrificación de aguas residuales industriales salinas
NI201700081A (es) Derivados de 5-[(piperazina-1-il)-3-oxo-propil]-imidazolidina-2,4-diona como inhibidores adamts para el tratamiento de la osteoartritis.
ECSP17038999A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
CL2016002615A1 (es) Heterociclil-sulfonas sustituidas con heteroarilo y su uso contra el dolor, accidente cerebrovascular, transtornos anímicos, epilepsia, esquizofrenia y trastornos neurodegenerativos.
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
BR112017002318A2 (pt) combinações de fármacos para tratar mieloma múltiplo.
CL2018001502A1 (es) Procedimiento para el tratamiento de efluente acuoso.
CL2015002612A1 (es) Oligonucletotidos antisentido para el tratamiento de células madre del cáncer.